Great question
I decided to use the dataset from ICIs, as it was much larger than that of OVs. Additionally, two phase III trials report pseudoprogression rates are similar between treatments (below). The larger phase III trial of T-Vec suggested the pseudoprogression rate was 14% in that trial, though I could not find where that was stated within the study itself. Thus, I went with 6% (5% if you take away SD from the ICI data), as this is where the majority of the data points.
Phase III trial of T-Vec (692 patients)
https://ascopubs.org/doi/full/10.1200/JCO.22.00343
Phase III trial of T-Vec (436 patients)
https://ascopubs.org/doi/10.1200/JCO.2014.58.3377
- Forums
- ASX - By Stock
- IMU
- Ann: VAXINIA and HER-Vaxx featured at the AACR Annual Meeting
Ann: VAXINIA and HER-Vaxx featured at the AACR Annual Meeting, page-241
-
- There are more pages in this discussion • 64 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.2¢ |
Change
-0.002(3.70%) |
Mkt cap ! $382.1M |
Open | High | Low | Value | Volume |
5.4¢ | 5.4¢ | 5.2¢ | $148.9K | 2.828M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
31 | 2436853 | 5.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.3¢ | 392814 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
31 | 2436853 | 0.052 |
43 | 4493294 | 0.051 |
58 | 4676760 | 0.050 |
19 | 2213068 | 0.049 |
20 | 815580 | 0.048 |
Price($) | Vol. | No. |
---|---|---|
0.053 | 392814 | 5 |
0.054 | 3612717 | 13 |
0.055 | 870851 | 7 |
0.056 | 2745820 | 14 |
0.057 | 859484 | 10 |
Last trade - 16.10pm 22/08/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
SS1
SUN SILVER LIMITED
Gerard O'Donovan, Executive Director
Gerard O'Donovan
Executive Director
SPONSORED BY The Market Online